SMOORE Launches Real-Time Monitoring Study on Nicotine Addiction

Jul.07.2022
SMOORE Launches Real-Time Monitoring Study on Nicotine Addiction
The world's largest e-cigarette manufacturer, SMOORE, partners with SIAT to study nicotine addiction and reduce nicotine levels in e-cigarettes.

The world's largest electronic cigarette manufacturer, SMOORE, has announced the launch of the world's first real-time monitoring research project on nicotine addiction.


The vaporization process between e-cigarettes and combustible cigarettes is vastly different, resulting in distinct physical and chemical properties obtained from vaporization and tobacco combustion, respectively.


Electronic cigarette company, SMOORE, has partnered with the Shenzhen Institute of Advanced Technology (SIAT) to undertake a new research project aimed at exploring ways to significantly reduce the nicotine strength in electronic cigarette products and ultimately lower it to non-addictive levels.


Under the direction of Nobel laureate Dr. Erwin Neher, the Neher Laboratory for Neural Plasticity in Shenzhen is the sixth laboratory in Shenzhen named after a Nobel laureate and the first dedicated to neuroscience. The laboratory focuses on researching the human brain and aims to better understand the mechanisms behind diseases and addictions through the use of the latest advanced techniques in modern neuroscience.


This joint study will investigate the secretion and metabolism of dopamine in the brains of animals, and use the data gathered to simulate the human brain state when nicotine is consumed. The laboratory will conduct controlled experiments by exposing test subjects to aerosol environments created by FEELM vaporization and combustion of tobacco.


The project aims to reduce the nicotine intake and subsequent dependence in adult e-cigarette users. This study will also assist SMOORE's research and development team in enhancing the design of e-cigarette devices by improving efficiency through modifying heating elements and atomizers to enhance the vaping experience.


Researchers involved in the project will monitor the aerosolization of e-liquid to gain a better understanding of nicotine absorption, distribution, metabolism in the human body. Additionally, the study will investigate how nicotine is absorbed by different organs to reveal the sensory satisfaction of e-cigarettes.


Dr. Xiong Yuming, Vice President of SMOORE Shenzhen Institute of Basic Research, stated that...


The process of vaporization between electronic cigarettes and combustible cigarettes is vastly different. Therefore, the physical and chemical properties obtained from vaporization and tobacco burning are also completely different. Our study focuses on the potential mechanisms of vaporization and tobacco burning, with the aim of exploring the delivery and absorption of nicotine to reduce the impact of these products on health.


This project is being supported by Southwest University in Chongqing, China. A phased report is expected to be released in the second half of 2022, which will outline the different effects of nicotine on the brain in electronic cigarettes and combustible tobacco products. This joint study on nicotine dependency aims to put an end to global nicotine addiction. Looking towards the future, FEELM aims to provide products that do not lead to nicotine dependency by reducing nicotine levels as close to zero as possible without compromising satisfaction.


This article is a compilation of third-party information, intended for educational and informational purposes only. The copyright for the compiled information belongs to the original media and authors. If there are any copyright infringements, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canadian Health Minister Marjorie Michel says she is not considering loosening retail restrictions on nicotine pouches. Canada regulates pouches containing 4 mg or less of nicotine per unit as non-prescription nicotine replacement therapy and requires newer NRT formats such as pouches to be sold from behind pharmacy counters. Meanwhile, Unsmoke Canada, linked to Philip Morris International's Canadian business, is pushing to allow pouches in convenience stores and other general retail outlets. Health Canada also acknowledges continued unauthorized sales, while recent research shows rising pouch use among Canadian youth aged 16 to 19.
Sep.24
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India's Ministry of Health and Family Welfare has directed states to step up enforcement against nicotine pouch sales, citing increased availability through online and offline channels and concern about nicotine exposure among children. Reuters reported that international brands including ZYN and White Fox are being sold in India. A study led by ICMR-NICPR found pouches in seven of 10 surveyed locations and identified 68 brands and 445 flavors online. Separately, India's Drugs Technical Advisory Board recommended in August that no new nicotine formulation be approved.
Regulations
Sep.28 by 2Firsts Perspectives
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-listed consumer goods group Supreme plc says it continues to expect FY27 trading to meet market expectations as the Vaping Products Duty takes effect on October 1, while maintaining a comparatively positive view of the new tax and compliance regime. Supreme has said the framework could increase compliance complexity for smaller operators and contribute to market consolidation, while its manufacturing, compliance and distribution scale may allow it to gain share. Its 88Vape brand will retain its value positioning.
Sep.18
Product | JT Refreshes Ploom CUBE Design and Expands Japan Retail Distribution, Targeting Younger Men and Female Users
Product | JT Refreshes Ploom CUBE Design and Expands Japan Retail Distribution, Targeting Younger Men and Female Users
Japan Tobacco (JT) launched a refreshed Ploom CUBE design in Japan on September 8, 2026, with broader convenience-store and tobacco-retail distribution planned from October 13. The updated device retains the existing Rounded Cube form and heating platform while replacing four previous body colors with Pebble White and Cobalt Black. JT is also introducing new Front Panels and Fabric Back Covers, although the new accessories are not compatible with the previous Ploom CUBE design. The company says the update is intended to broaden appeal among younger male and female users.
Sep.09
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22